Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

Key Inclusion Criteria:

• Prior participation in an Aimmune AR101 clinical study or any future clinical studythat identifies ARC008 as a follow-on study option in the protocol

• Written informed consent and/or assent from subjects/guardians as appropriate

• Use of effective birth control by sexually active female subjects of childbearingpotential

Key Exclusion Criteria:

• Did not complete a minimum of 3 months of AR101 maintenance therapy if the subjectwas assigned to AR101 in the parent study

• Currently receiving or received within 5 years prior to Screening any type of peanutor other food allergen immunotherapy, except AR101 or unless allowed in the parentstudy, and except during the follow-up observation period in this study

• Discontinued early from the parent study